Skip to main content

Preclinical Immunology & Autoimmune Deal Benchmarks

Median Upfront
$61M
Range: $22M - $104M
Total Deal Value
$878M
Range: $395M - $1.4B
Royalty Rate
5.5% - 10.9%
Tiered up to 14.9%
Dev Milestones
$368M
Range: $168M - $566M

Market Analysis

Preclinical immunology & autoimmune licensing deals carry a median total deal value of $878M, with upfront payments ranging from $22M to $104M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 7% to upfront and 93% to milestones.

The immunology & autoimmune landscape at the preclinical stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $368M, regulatory milestones contribute $245M, and commercial milestones reach $204M. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.

Royalty rates for preclinical immunology & autoimmune deals range from 5.5% to 10.9% at the base tier, with high-tier escalation to 14.9%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for preclinical immunology & autoimmune deals?
Preclinical immunology & autoimmune deals average $61M in upfront payments, ranging from $22M to $104M. The upfront allocation of 7% of total deal value reflects the clinical stage risk profile.
How are preclinical immunology & autoimmune deal milestones structured?
Milestones account for approximately 93% of total deal value. Development milestones ($368M) represent the largest component, followed by commercial milestones ($204M) and regulatory milestones ($245M).
What royalty rates are typical for preclinical immunology & autoimmune licensing?
Base royalty rates range from 5.5% to 10.9%, with tiered escalation to 9.5%-14.9% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included